Tevogen Bio

Yahoo Finance • 3 days ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Bio Inc Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly every time, dramatically rai... Full story

Yahoo Finance • 5 days ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the poten... Full story

Yahoo Finance • 9 days ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr.... Full story

Yahoo Finance • 18 days ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a pan... Full story

Yahoo Finance • 19 days ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared a... Full story

Yahoo Finance • 20 days ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic... Full story

Yahoo Finance • 24 days ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on im... Full story

Yahoo Finance • 25 days ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at... Full story

Yahoo Finance • last month

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not ref... Full story

Yahoo Finance • last month

Eli Lilly and Company (LLY): A Bull Case Theory

We came across a bullish thesis on Eli Lilly and Company on Arya’s Substack by Arya. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company's share was trading at $695.33 as of August 25th. LLY’s trailing and fo... Full story

Yahoo Finance • last month

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Compa... Full story

Yahoo Finance • last month

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institution... Full story

Yahoo Finance • last month

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Provider... Full story

Yahoo Finance • last month

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunother... Full story

Yahoo Finance • last month

Tevogen Bio Holdings reports Q2 results

* Tevogen Bio Holdings press release [https://seekingalpha.com/pr/20205604-tevogen-delivers-stronger-second-quarter-and-first-half-2025-financial-results-with-reduced] (NASDAQ:TVGN [https://seekingalpha.com/symbol/TVGN]): Q2 loss from ope... Full story

Yahoo Finance • last month

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and ant... Full story

Yahoo Finance • last month

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his personal shares of common stock to the... Full story

Yahoo Finance • last month

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to... Full story

Yahoo Finance • last month

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. “Tevogen is an asset-rich enterp... Full story

Yahoo Finance • 2 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherap... Full story